Cigarette smoking abstinence at follow-up at 12 months among US adults who regularly used Electronic Nicotine Delivery Systems and smoked in the past year: A prospective cohort study
Amy L. Nyman, Katherine C. Henderson, David L. Ashley, Claire A. Spears, Jidong Huang, Zongshuan Duan, Scott R. Weaver

TL;DR
This study found that people who used Juul or Alto e-cigarettes to quit smoking were more likely to remain smoke-free after one year, despite no overall difference between the two brands.
Contribution
The study identifies specific sociodemographic and behavioral factors associated with smoking abstinence among ENDS users.
Findings
No overall difference in smoking abstinence was found between Juul and Alto users after one year.
Users who had already quit smoking by baseline were more likely to remain abstinent if they used Juul.
Younger age, White ethnicity, and using ENDS to quit smoking were associated with higher abstinence rates.
Abstract
Regular use of electronic nicotine delivery systems (ENDS) by people who smoke cigarettes may impact smoking trajectories. ENDS brands are used by different populations in different ways, but their associations with smoking cessation are not well understood. This study evaluated whether regular use of Juul or Alto ENDS differently impacted smoking abstinence one year later among adults who had smoked cigarettes. This prospective cohort study surveyed a national sample of US adults who used ENDS in 2022–2023 and again after one year to assess cigarette smoking. Multivariable logistic regression models used data from 237 people who had smoked cigarettes in the past year and regularly used ENDS products Juul or Alto at baseline to examine the characteristics and behaviors associated with abstaining from cigarette smoking at follow-up at 12 months. Whereas no overall differences in…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
|
|
|
|
|
|---|---|---|---|
|
| |||
| Juul | 42.6 (101) | 0.94 | 0.45–1.98 |
| Alto | 57.4 (136) | 1 | |
| 18–29 | 21.5 (51) |
|
|
| ≥30 | 78.5 (186) | 1 | |
|
| |||
| Cis Male | 35.4 (84) | 1.05 | 0.52–2.13 |
| Cis Female | 64.6 (153) | 1 | |
|
| |||
| White, NH | 74.3 (176) |
|
|
| Other | 25.7 (61) | 1 | |
|
| |||
| Lower than Bachelor’s degree | 73.4 (174) | 0.93 | 0.42–2.04 |
| Bachelor’s degree or higher | 26.6 (63) | 1 | |
|
| |||
| Not a sexual minority | 75.5 (179) | 1.00 | 0.44–2.30 |
| Sexual minority | 24.5 (58) | 1 | |
|
| |||
| No SPD | 77.2 (183) | 0.92 | 0.40–2.10 |
| SPD | 22.8 (54) | 1 | |
|
| |||
| Not currently smoking | 43.0 (102) |
|
|
| Currently smoking | 57.0 (135) | 1 | |
|
| |||
| ≤3% | 23.6 (56) | 1.03 | 0.43–2.48 |
| 5% | 76.4 (181) | 1 | |
|
| |||
| Menthol/Mint | 60.3 (143) | 1.04 | 0.40–2.72 |
| Tobacco | 39.7 (94) | 1 | |
|
| |||
| 15–25 | 16.9 (40) | 1.30 | 0.53–3.22 |
| 26–30 | 83.1 (197) | 1 | |
|
| |||
| Using to quit/remain quit | 77.2 (183) |
|
|
| Not using to quit/remain quit | 22.8 (54) | 1 | |
|
| |||
| Menthol | 51.5 (122) |
|
|
| Tobacco | 48.5 (115) | 1 | |
|
| |||
| Juul (vs Alto) | 1.34 | 0.59–3.07 | |
| Age (years) 18–29 (vs ≥30) |
|
| |
| Regular ENDS product × age |
|
| |
|
| |||
| Juul (vs Alto) | 0.20 | 0.03–1.04 | |
|
| |||
| Juul (vs Alto) | 0.63 | 0.27–1.43 | |
| Not currently smoking at baseline (vs currently smoking) |
|
| |
| Regular ENDS product × baseline smoking status |
|
| |
|
| |||
| Juul (vs Alto) |
|
| |
|
| |||
| Juul (vs Alto) | 0.78 | 0.31–1.97 | |
| Male (vs Female) | 0.83 | 0.30–2.25 | |
| Regular ENDS product × gender | 1.60 | 0.39–6.63 | |
|
| |||
| Juul (vs Alto) | 0.76 | 0.18–3.11 | |
| White, NH (vs Other) | 2.64 | 0.88–8.21 | |
| Regular ENDS product × race/ethnicity | 1.35 | 0.26–7.21 | |
|
| |||
| Juul (vs Alto) | 1.68 | 0.41–6.89 | |
| Lower than Bachelor’s degree (vs Bachelor’s degree or higher) | 1.46 | 0.42–5.01 | |
| Regular ENDS product × education level | 0.46 | 0.09–2.29 | |
|
| |||
| Juul (vs Alto) | 0.39 | 0.08–1.86 | |
| Not a sexual minority (vs sexual minority) | 0.69 | 0.24–1.91 | |
| Regular ENDS product × sexual orientation | 3.03 | 0.53–19.02 | |
|
| |||
| Juul (vs Alto) | 0.50 | 0.11–2.23 | |
| No SPD (vs SPD) | 0.62 | 0.19–1.97 | |
| Regular ENDS product × serious psychological distress (SPD) | 2.25 | 0.43–12.58 | |
|
| |||
| Juul (vs Alto) | 0.97 | 0.43–2.23 | |
| ≤3% nicotine (vs 5% nicotine) | 1.09 | 0.37–3.27 | |
| Regular ENDS product × nicotine content of [Juul/Alto] | 0.86 | 0.16–4.84 | |
|
| |||
| Juul (vs Alto) | 1.45 | 0.45–4.79 | |
| ENDS flavor menthol/mint (vs tobacco) | 1.1 | 0.24–5.10 | |
| Cigarette flavor menthol (vs tobacco) | 3.37 | 0.36–32.25 | |
| Regular ENDS product × flavor of [Juul/Alto] used most often | 1.16 | 0.13–10.11 | |
| Regular ENDS product × cigarette flavor used most often | 0.70 | 0.01–37.82 | |
| Flavor of [Juul/Alto] used most often × cigarette flavor used most often | 1.19 | 0.09–16.83 | |
| Regular ENDS product × flavor of [Juul/Alto] used most often × cigarette flavor used most often | 0.45 | 0.01–37.93 | |
|
| |||
| Juul (vs Alto) | 0.98 | 0.44–2.22 | |
| 15–25 days used per month (vs 26–30 days used per month) | 1.46 | 0.39–5.65 | |
| Regular ENDS product × days used [Juul/Alto] per month | 0.81 | 0.13–4.80 | |
|
| |||
| Juul (vs Alto) | 1.41 | 0.31–6.53 | |
| Using product to quit (vs not using product to quit) |
|
| |
| Regular ENDS product × using [Juul/Alto] to quit cigarettes | 0.60 | 0.11–3.25 | |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSmoking Behavior and Cessation · Substance Abuse Treatment and Outcomes · Nicotinic Acetylcholine Receptors Study
INTRODUCTION
There is much debate over the impact of using electronic nicotine delivery systems (ENDS) on cigarette smoking trajectories, with numerous studies concluding ENDS use may aid smoking cessation^1,2^ and others suggesting ENDS use may sustain dual use or inhibit quitting^3,4^. Understanding of the long-term outcomes of ENDS use on cigarette smoking can ensure future scientific and policy recommendations that are in the best interest of public health.
Many studies examining the impact of ENDS use on smoking cessation focus on ENDS use in general^5^ or on one specific ENDS product^6^, and therefore do not compare the impact of similar ENDS models from different brands. However, some recent research highlights differences in user characteristics, reasons for use, or usage patterns by ENDS brand or model^7-9^, indicating a need to understand the impact of use of comparable products on subsequent cigarette smoking outcomes. If one product is more effective at promoting smoking cessation and its users differ sociodemographically, some populations may be differentially impacted, with implications for health equity. A recent study found Juul and Puff Bar were more often reported as the usual brand for Black and Hispanic youth and young adults than by those of other races and ethnicities^8^. Another study noted ENDS device type differences between female and male ENDS users^9^. Still other recent findings indicate those who have smoked cigarettes in the past year who regularly use Juul were less likely to not be currently smoking, were younger, and more likely to identify as a racial or ethnic minoritized group than those who regularly use Vuse Alto^7^. Longitudinal studies following users of similar ENDS products who currently or recently smoked cigarettes are necessary to understand the ultimate effects of dual use on cessation.
This study examines differences in sociodemographic characteristics and usage patterns of leading ENDS products Juul and Alto, and measures cigarette smoking abstinence after one year among those who currently or recently smoked cigarettes at baseline. We aim to determine whether regular usage of two comparable ENDS products is associated with differential smoking outcomes at follow-up at 12 months, in interaction with or independent of sociodemographic or behavioral characteristics.
METHODS
Participants and procedures
This prospective cohort study included a national sample of 759 US adults who currently or formerly smoked combusted cigarettes, used select market-leading ENDS brands, and participated in a 12-month longitudinal survey study assessing cigarette smoking and ENDS usage (September 2022–July 2024). Recruitment occurred via paid social media advertisements from September 2022 through July 2023. To be eligible for the larger study, participants needed to be at least 18 years old, current US residents, and had to report past 30-day use of one or more specific ENDS products. Participants who completed the baseline survey and had smoked cigarettes in the past year, as well as those who had used an ENDS product that was unauthorized for sale in the US at the time of the baseline survey, were invited to complete the follow-up survey 12 months later. This study focuses on the subsample that smoked cigarettes in the past year and regularly used Juul or Alto (but not both) at the baseline survey. Of the 320 participants who reported past-year cigarette smoking and regular use of either Juul or Alto (but not both) at the baseline survey, the analytic sample for this study uses data from the 237 participants who completed the survey at follow-up at 12 months and were not missing data on the covariates included in the present study (see Supplementary file Figure S1 for a flowchart of participant details). Full study details have been previously published^7^.
Measures
The outcome was smoking abstinence at follow-up at 12 months. The independent variable was whether participants regularly used Juul versus Alto at baseline. Covariates included nicotine concentration, most commonly used Juul/Alto flavor (tobacco vs menthol/mint), number of days Juul/Alto used in the past month, using Juul or Alto to quit smoking or remain quit, current cigarette smoking status, flavor of respondents’ regular cigarette brand (tobacco vs menthol), presence of serious psychological distress, and sociodemographic characteristics (age, gender, race/ethnicity, education level, sexual orientation) at baseline, details of which are given in Supplementary file Table S1 and described elsewhere^7^.
Data analysis
A main-effects multivariable logistic regression model was used to predict smoking abstinence at follow-up at 12 months, with adjustment for covariates. Subsequent models examined two-way interactions between Juul versus Alto use and each covariate, and the three-way interaction with cigarette flavor and Juul or Alto flavor. Simple main effects were examined where a significant interaction effect was obtained. Odds ratios (ORs) with 95% profile likelihood confidence intervals were obtained with SPSS v. 29 ^10^.
RESULTS
Nearly two-thirds of the sample (62.4%) were smoking abstinent at follow-up at 12 months, including 40.0% of people who currently smoked at baseline. Adjusting for all covariates, there was no difference in the odds of smoking abstinence between Juul versus Alto users (Table 1, Model 1). However, interaction analyses indicated that this association differed according to age and baseline smoking status. Juul use was positively, albeit non-significantly associated (vs Alto use) with smoking abstinence among those aged ≥30 years (AOR=1.34), whereas it was negatively, albeit also non-significantly associated with smoking abstinence among young adults (aged 18–29 years) (AOR=0.20) (Model 2b). Among those who were currently smoking cigarettes at baseline, there was no significant difference in smoking abstinence between Juul and Alto users; whereas among those who were past year but not currently smoking at baseline, Juul users were more likely than Alto users to have remained abstinent at follow-up at 12 months (AOR=7.07) (Model 3b). No other interaction effects were statistically significant (Models 4–12).
Younger adults (aged 18–29 years) (AOR=3.64), those identifying as non-Hispanic White (AOR=3.03), not currently smoking at baseline (AOR=20.25), using their product (Juul or Alto) to quit smoking (AOR=2.77), or smoking menthol cigarettes (AOR=2.54) were each more likely to be smoking abstinent at follow-up at 12 months than their respective counterparts, adjusting for all other covariates (Table 1, Model 1). No significant differences in smoking abstinence were observed for gender, education level, sexual orientation, serious psychological distress, nicotine concentration, Juul/ Alto flavor, or days used per month when adjusting for other covariates.
DISCUSSION
In July 2025, the US FDA authorized marketing of Juul, which joined Alto and a limited list of other ENDS products as authorized for sale in the US^11^, after retracting a prior market denial order for Juul^12^. Understanding differences in cigarette smoking outcomes between Juul and Alto, two US market-leading brands, could inform consumers, health researchers and practitioners, and regulators. This novel study compares smoking outcomes between adults who used Juul versus Alto using longitudinal data.
Prior cross-sectional research found differences in readiness to quit, use of ENDS to quit smoking, and sociodemographic characteristics between those who use Alto versus Juul. The study reported that those who smoke cigarettes and use Alto might have greater success in subsequently quitting smoking^7^. Moreover, while Juul and Alto are both similarly designed closed-system pod ENDS with similar levels of nicotine concentration in a nicotine-salt formulation, Alto may generate greater nicotine yields^13^. However, the current prospective cohort study found no overall differences in smoking abstinence at follow-up at 12 months between those who regularly used Juul and those who regularly used Alto at baseline. Yet among those who smoked in the past year but not currently at baseline, participants were more likely to be abstinent 12 months later if they regularly used Juul than if they regularly used Alto. This suggests that those who formerly smoked who use Juul are less likely to subsequently relapse to smoking than former smokers who use Alto. However, our results indicate tentative evidence that this pattern might not extend to younger adults. Specifically, we found younger adults who regularly used Juul might be at a relative disadvantage compared to those who used Alto based on an age by Juul versus Alto use interaction. Despite this interaction, the statistical effect for Juul versus Alto was non-significant among both younger adults and adults aged >29 years, suggesting that this study may be insufficiently powered to detect a difference for one or both age groups. Further research with larger samples will be needed to reconcile these findings.
While randomized controlled trials have supported the efficacy of newer generation ENDS for smoking cessation, longitudinal observational studies have been mixed^1,14^. More than three-fourths of our sample reported they were using Juul or Alto to abstain from smoking at baseline, and 62.4% were self-reported abstinent from smoking at follow-up. However, this study was not designed to evaluate the efficacy or effectiveness of Juul or Alto for smoking cessation, and generalization of findings is limited by the convenience sample and lack of biochemical verification of smoking abstinence.
Interestingly, this study found those who smoked menthol cigarettes were more likely to be abstinent at follow-up than those who smoked non-menthol cigarettes. Whereas this is in contrast to a prior research finding that adults who smoke menthol cigarettes were less likely to quit smoking, the prior study also found that ENDS use was associated with smoking cessation and more strongly for those who smoked menthol cigarettes^15^. Furthermore, our study adjusted for ethnic/racial minoritized status, which is associated with both menthol cigarette use and poor smoking cessation outcomes.
Limitations
This study has several limitations. First, use of a convenience sample limits the generalizability of the findings. Second, this study relies on observational data at two time points with a one-year interval, thus limiting causal inference and examination of detailed trajectories of product use and smoking behavior. Finally, self-reports of product use may lead to misclassification and social desirability bias.
CONCLUSIONS
Though differences exist in the characteristics and usage patterns of those who regularly use Juul and Alto ENDS products, this prospective cohort study found very limited differences in smoking abstinence after one year among those who had currently or recently smoked cigarettes at baseline and regularly used either Juul or Alto. Relapse to smoking may be less likely with Juul than with Alto, which warrants further study.
Supplementary Material
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Lindson N, Butler AR, Mc Robbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2025;1(1):CD 010216. doi:10.1002/14651858.CD 010216.pub 933052602 PMC 8094228 · doi ↗ · pubmed ↗
- 2Levett JY, Filion KB, Reynier P, Prell C, Eisenberg MJ. Efficacy and safety of e-cigarette use for smoking cessation: a systematic review and meta-analysis of randomized controlled trials. Am J Med. 2023;136(8):804-813.e 4. doi:10.1016/j.amjmed.2023.04.01437148992 · doi ↗ · pubmed ↗
- 3Kaplan B, Galiatsatos P, Breland A, Eissenberg T, Cohen JE. Effectiveness of ENDS, NRT and medication for smoking cessation among cigarette-only users: a longitudinal analysis of PATH Study wave 3 (2015-2016) and 4 (2016-2017), adult data. Tob Control. 2023;32(3):302-307. doi:10.1136/tobaccocontrol-2020-05644834526410 PMC 10176346 · doi ↗ · pubmed ↗
- 4Quach NE, Pierce JP, Chen J, et al. Daily or nondaily vaping and smoking cessation among smokers. JAMA Netw Open. 2025;8(3):e 250089. doi:10.1001/jamanetworkopen.2025.008940042845 PMC 11883493 · doi ↗ · pubmed ↗
- 5Coffey M, Cooper-Ryan AM, Houston L, Thompson K, Cook PA. Using e-cigarettes for smoking cessation: evaluation of a pilot project in the North West of England. Perspect Public Health. 2020;140(6):351-361. doi:10.1177/175791392091243632389072 PMC 7683886 · doi ↗ · pubmed ↗
- 6Foulds J, Cobb CO, Yen MS, et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tob Res. 2022;24(7):955-961. doi:10.1093/ntr/ntab 24734850164 PMC 9391685 · doi ↗ · pubmed ↗
- 7Nyman AL, Henderson KC, Holland J Jr, et al. Cross-sectional comparison of sociodemographic and tobacco use characteristics of U.S. adults who regularly use leading electronic nicotine delivery system (ENDS) products. Tob Induc Dis. 2025;23(December):193. doi:10.18332/tid/209827 PMC 1269931941394889 · doi ↗ · pubmed ↗
- 8Kreslake JM, Bertrand A, Minter T, Schillo BA. E-cigarette brand use by race/ethnicity in a US sample of adolescent and young adult e-cigarette users, 2022-2023. Nicotine Tob Res. 2025;27(5):849-855. doi:10.1093/ntr/ntae 17439240795 · doi ↗ · pubmed ↗
